ATRA alleviates doxorubicin-induced cardiomyocyte ferroptosis by suppressing KEAP1-mediated NRF2 degradation
This study demonstrates that all-trans retinoic acid (ATRA) protects against doxorubicin-induced cardiomyocyte ferroptosis by disrupting the KEAP1-NRF2 interaction to stabilize NRF2 and activate the NRF2-SLC7A11 antioxidant pathway.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Cancer treatment has long been a double-edged sword. One of the most powerful weapons in the oncologist's arsenal is a drug called doxorubicin, a chemotherapy agent used to fight a wide variety of tumors. However, this drug carries a heavy price: it can severely damage the heart. While the drug attacks cancer cells, it also inflicts a specific type of injury on the heart muscle cells, causing them to die in a process driven by a buildup of toxic fats and a loss of the cell's natural ability to clean up oxidative waste. This form of cell death, known as ferroptosis, leaves the heart weak and unable to pump blood effectively, often limiting how much of the life-saving drug a patient can receive. Scientists have been searching for a way to shield the heart from this damage without weakening the drug's ability to kill cancer.
A team of researchers at the Affiliated Hospital of Jiangsu University and other institutions in China has identified a potential shield. They investigated whether a compound called all-trans retinoic acid, or ATRA, could protect heart cells from the ravages of doxorubicin. ATRA is a form of vitamin A that is already used in medicine to treat certain cancers and skin conditions. The researchers discovered that ATRA does indeed act as a protective agent, but it works by turning on a specific internal defense system within the heart cells. Instead of simply neutralizing the poison directly, ATRA stops the cell's own security system from dismantling its primary antioxidant, a protein called NRF2. By keeping this protein safe and active, ATRA allows the heart cells to maintain their defenses against the toxic fats that cause cell death.
The story of how this protection works begins with the mechanism of the injury itself. When doxorubicin enters a heart cell, it triggers a cascade of events that leads to the accumulation of iron and the production of reactive oxygen species, which are unstable molecules that damage cellular structures. This damage specifically targets the cell's membranes, causing them to rust and break down in a process called lipid peroxidation. To survive, cells rely on a molecule called glutathione to neutralize these threats. A key transporter protein, SLC7A11, is responsible for bringing in the raw materials needed to make glutathione. The researchers found that doxorubicin shuts down the production of SLC7A11, leaving the cell defenseless.
In their experiments, the team treated human heart muscle cells with doxorubicin and observed the expected decline in cell health. The cells lost their ability to produce glutathione, their levels of toxic lipid byproducts soared, and they began to die. However, when the researchers added ATRA to the mix, the outcome changed dramatically. The heart cells remained alive, their levels of glutathione were restored, and the toxic lipid buildup was cleared away. The protective effect was so strong that it was comparable to using a known inhibitor of ferroptosis, a drug specifically designed to stop this type of cell death.
To understand exactly how ATRA achieved this, the researchers looked deeper into the cell's machinery. They focused on a protein called NRF2, which acts as a master switch for antioxidant genes, including the gene that produces the vital SLC7A11 transporter. Under normal conditions, a protein called KEAP1 acts as a tagger, marking NRF2 for destruction by the cell's waste disposal system, the proteasome. This ensures that NRF2 levels remain low when they are not needed. The researchers discovered that doxorubicin accelerates this tagging process, causing NRF2 to vanish and leaving the cell without its antioxidant defenses.
ATRA intervenes by disrupting the interaction between KEAP1 and NRF2. The study showed that ATRA prevents KEAP1 from grabbing onto NRF2, allowing the antioxidant protein to accumulate and move into the cell's nucleus. Once inside the nucleus, NRF2 turns on the genes needed to rebuild the cell's defenses, specifically boosting the production of SLC7A11. This chain reaction restores the cell's ability to make glutathione and survive the toxic assault. The researchers confirmed this mechanism by creating cells where the KEAP1 protein was mutated at a specific spot, known as Arg415. In these mutated cells, ATRA could no longer prevent the destruction of NRF2, and the protective effect vanished. This proved that the specific interaction at Arg415 is essential for ATRA to work.
The team did not stop at cell cultures; they tested these findings in living mice. They divided the animals into groups, with some receiving doxorubicin alone and others receiving doxorubicin along with ATRA. The mice treated with doxorubicin alone showed clear signs of heart damage, including enlarged hearts and a significant drop in pumping efficiency. In contrast, the mice that received ATRA alongside the chemotherapy drug maintained a much healthier heart size and function. Their hearts pumped blood more effectively, and their tissue showed far less scarring and cell death. The levels of protective proteins in their heart tissue mirrored the results seen in the cells, confirming that the mechanism works in a complex living system.
While the results are promising, the researchers are careful to note that this is a preclinical study. The work was conducted in human cell lines and mice, and more research is needed to determine if ATRA can safely protect human patients without interfering with the cancer-killing power of doxorubicin. The study does suggest, however, that the KEAP1-NRF2 pathway is a viable target for protection. By understanding how ATRA stabilizes NRF2 through a specific molecular handshake at Arg415, scientists have uncovered a potential strategy to decouple the life-saving benefits of chemotherapy from its most dangerous side effects. This approach offers a new direction for protecting the heart, relying on the body's own antioxidant systems rather than just scavenging toxins.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.